Literature DB >> 16337389

Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer.

Christophoros N Foroulis1, James A C Thorpe.   

Abstract

OBJECTIVE: Esophagectomy is the standard treatment for high-grade dysplasia (HGD) and intramucosal adenocarcinoma (IMC) arising within Barrett's esophagus. Results of photodynamic therapy (PDT) were retrospectively studied to evaluate the effectiveness of PDT in ablating HGD and/or IMC complicating Barrett's esophagus.
METHODS: Thirty-one patients unfit for or refusing esophagectomy (male: 20, mean age: 73.4+/-9.3 years) underwent Porfimer sodium PDT ablation of their HGD (15 patients), HGD plus IMC (10 patients) or submucosal/limited T2 adenocarcinoma (6 patients). The mean Barrett's length was 5.8+/-2.2 cm. Pre-PDT endoscopic mucosal resection or Nd:YAG laser ablation of mucosal nodularity within Barrett's segment was offered in six patients.
RESULTS: The main PDT complications were esophagitis (16.1%), photoreactions (12.9%) and stricture requiring dilatation (6.25%). The median post-PDT follow-up was 14 months. The long-term results were (a) for HGD/IMC: initial complete response (endoscopic and histologic absence of HGD-IMC) to PDT was observed in 80.95% of patients, partial response (no endoscopic abnormality, residual IMC-HGD on biopsy) in 9.52%, no response in 9.52% (the recurrence rate after an initial complete response was 17.64%) and (b) for T1b/limited T2 tumors: two patients died from cancer after 24 and 46 months, no evidence of tumor was found in two patients after 12 and 19 months and tumor recurrence was seen in two after 15 and 17 months. The mean survival was 22.1+/-12.3 months.
CONCLUSIONS: PDT is effective in ablating HGD/IMC complicating Barrett's esophagus in the majority of cases, while it also seems to be quite effective in treating T1b/limited T2 carcinomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16337389     DOI: 10.1016/j.ejcts.2005.10.033

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  8 in total

Review 1.  Tumor ablation and nanotechnology.

Authors:  Rachel L Manthe; Susan P Foy; Nishanth Krishnamurthy; Blanka Sharma; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2010-10-07       Impact factor: 4.939

Review 2.  Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review.

Authors:  Nathan A Gray; Robert D Odze; Stuart Jon Spechler
Journal:  Am J Gastroenterol       Date:  2011-08-09       Impact factor: 10.864

3.  Effect and mechanism of 5-aminolevulinic acid-mediated photodynamic therapy in esophageal cancer.

Authors:  Xiaohua Chen; Peng Zhao; Fengsheng Chen; Libo Li; Rongcheng Luo
Journal:  Lasers Med Sci       Date:  2010-07-30       Impact factor: 3.161

4.  Apoptotic effects of Photofrin-Diomed 630-PDT on SHEEC human esophageal squamous cancer cells.

Authors:  Shegan Gao; Mengxi Zhang; Xiaojuan Zhu; Zhifeng Qu; Tanyou Shan; Xuanhu Xie; Ying Wang; Xiaoshan Feng
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 5.  Treatment for Barrett's oesophagus.

Authors:  Jonathan Re Rees; Pierre Lao-Sirieix; Angela Wong; Rebecca C Fitzgerald
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

6.  Outcomes following laparoscopic transhiatal esophagectomy for esophageal cancer.

Authors:  J Christian Cash; Joerg Zehetner; Bobak Hedayati; Nikolai A Bildzukewicz; Namir Katkhouda; Rodney J Mason; John C Lipham
Journal:  Surg Endosc       Date:  2013-10-08       Impact factor: 4.584

Review 7.  Preserving fertility in young patients with endometrial cancer: current perspectives.

Authors:  Eleftheria Kalogera; Sean C Dowdy; Jamie N Bakkum-Gamez
Journal:  Int J Womens Health       Date:  2014-07-29

8.  Tyrosine kinase inhibitor induced growth factor receptor upregulation enhances the efficacy of near-infrared targeted photodynamic therapy in esophageal adenocarcinoma cell lines.

Authors:  Elmire Hartmans; Matthijs D Linssen; Claire Sikkens; Afra Levens; Max J H Witjes; Gooitzen M van Dam; Wouter B Nagengast
Journal:  Oncotarget       Date:  2017-05-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.